Prospectively documented childhood abuse is associated with a significantly increased long-term risk for adult migraine in men, and depression seems to partially mediate this rela ...

The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment ...

Adults with elevated emotional dysfunction report higher current ADHD symptoms regardless of an actual ADHD diagnosis.

The FDA accepted the NDA for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027.

The use of benzodiazepines among older adults in the US decreased and then plateaued after the COVID-19 pandemic.

Virtual military sexual trauma-focused group therapy improves post-traumatic stress disorder symptoms in veterans.

Mood instability increases the annual use of child and adolescent mental health services among youth with ADHD and ASD.

Anxiety and depression are common in patients with idiopathic pulmonary fibrosis and are significantly affected by the diagnostic criteria used.

The proportion of suspected suicide attempts vs all emergency department visits decreased between 2021 and 2025.

Men hospitalized for first-episode psychosis with cannabis exposure vs no cannabis exposure showed distinct clinical and cognitive features.

Twice-daily stable lithium carbonate dosing seems to offer more stable brain lithium levels among euthymic individuals with bipolar disorder.

Prefrontal transcranial pulse stimulation offers some antidepressant effects among patients with major depressive disorder.